These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1758 related articles for article (PubMed ID: 30658519)

  • 1. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature.
    Milosevic I; Vujovic A; Barac A; Djelic M; Korac M; Radovanovic Spurnic A; Gmizic I; Stevanovic O; Djordjevic V; Lekic N; Russo E; Amedei A
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
    Xie C; Halegoua-DeMarzio D
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal microbiota in liver disease.
    Haque TR; Barritt AS
    Best Pract Res Clin Gastroenterol; 2016 Feb; 30(1):133-42. PubMed ID: 27048904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
    Cho MS; Kim SY; Suk KT; Kim BY
    J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of gut microbiota in chronic liver diseases, and treatment possibilities].
    Hagymási K; Bacsárdi A; Egresi A; Berta E; Tulassay Z; Lengyel G
    Orv Hetil; 2018 Sep; 159(36):1465-1474. PubMed ID: 30175608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature.
    Giuffrè M; Campigotto M; Campisciano G; Comar M; Crocè LS
    Am J Physiol Gastrointest Liver Physiol; 2020 May; 318(5):G889-G906. PubMed ID: 32146836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of Gut Microbiota-Brain Axis by Probiotics, Prebiotics, and Diet.
    Liu X; Cao S; Zhang X
    J Agric Food Chem; 2015 Sep; 63(36):7885-95. PubMed ID: 26306709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Liver diseases: The pathogenetic role of the gut microbiome and the potential of treatment for its modulation].
    Aitbaev KA; Murkamilov IT; Fomin VV
    Ter Arkh; 2017; 89(8):120-128. PubMed ID: 28914862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
    Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
    Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.
    Ebrahimzadeh Leylabadlo H; Ghotaslou R; Samadi Kafil H; Feizabadi MM; Moaddab SY; Farajnia S; Sheykhsaran E; Sanaie S; Shanehbandi D; Bannazadeh Baghi H
    Eur J Clin Microbiol Infect Dis; 2020 Apr; 39(4):613-627. PubMed ID: 31828683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy.
    Fianchi F; Liguori A; Gasbarrini A; Grieco A; Miele L
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Dysbiosis for the Treatment of Liver Disease.
    Anand G; Zarrinpar A; Loomba R
    Semin Liver Dis; 2016 Feb; 36(1):37-47. PubMed ID: 26870931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysbiosis and liver diseases (Review).
    Nishikawa H; Fukunishi S; Asai A; Yokohama K; Ohama H; Nishiguchi S; Higuchi K
    Int J Mol Med; 2021 Sep; 48(3):. PubMed ID: 34328191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease Progression.
    Mungamuri SK; Vijayasarathy K
    Crit Rev Oncog; 2020; 25(1):57-70. PubMed ID: 32865911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nutritional Approach Targeting Gut Microbiota in NAFLD-To Date.
    Moszak M; Szulińska M; Walczak-Gałęzewska M; Bogdański P
    Int J Environ Res Public Health; 2021 Feb; 18(4):. PubMed ID: 33567710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fighting Fatty Liver Diseases with Nutritional Interventions, Probiotics, Symbiotics, and Fecal Microbiota Transplantation (FMT).
    Nobili V; Mosca A; Alterio T; Cardile S; Putignani L
    Adv Exp Med Biol; 2019; 1125():85-100. PubMed ID: 30578461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microbiota, Liver Diseases, and Alcohol.
    Cassard AM; Gérard P; Perlemuter G
    Microbiol Spectr; 2017 Aug; 5(4):. PubMed ID: 28840806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 88.